The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease

• Published in: Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2024-08, Vol.34 (8), p.1922-1931
• Main Authors: Yin, Yufeng, Zhu, Weijia, Xu, Qingling
• Format: Article
• Language: English
• Subjects: Adult; Aged; Cause of Death; Disease Progression; Female; Hepatic fibrosis; Humans; Inflammation; Inflammation - blood; Inflammation - diagnosis; Inflammation - mortality; Inflammation Mediators - blood; Liver Cirrhosis - blood; Liver Cirrhosis - diagnosis; Liver Cirrhosis - mortality; Liver disorders; Male; Middle Aged; Mortality; NHANES; Nutrition Surveys; Predictive Value of Tests; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; United States - epidemiology
• ISSN: 0939-4753; 1590-3729; 1590-3729
• DOI: 10.1016/j.numecd.2024.04.018

The systemic inflammation response index (SIRI) is associated with various diseases with inflammatory components, but its relationship with the progression of hepatic fibrosis and survival outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is still unclear. This study was designed to investigate the potential associations between the SIRI and advanced hepatic fibrosis (AHF) as well as between the SIRI and long-term outcomes in individuals with MASLD. A prospective cohort study was conducted using data gathered from the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2016. Weighted binary logistic regression, the Cox proportional hazards model, and time-dependent receiver operating characteristic (ROC) analyses were employed to assess the relationships among the SIRI, AHF, and mortality in patients with MASLD. Our study included a total of 5126 patients with MASLD. A higher SIRI was significantly associated with increased odds of AHF (OR 1.55, 95% CI 1.22, 1.96). According to the survival analyses, a higher SIRI was associated with greater all-cause (HR 1.19, 95% CI 1.15, 1.22) and cardiovascular mortality (HR 1.25, 95% CI 1.19, 1.32) after adjustment. The time-dependent ROC analysis indicated that the SIRI had a modest predictive value for discriminating MASLD individuals at higher versus lower mortality risk over 3-year, 5-year, and 10-year follow-up. The SIRI is a promising tool for identifying MASLD individuals at risk of progressing to AHF and for predicting mortality outcomes. •Higher SIRI is associated with increased odds of advanced hepatic fibrosis in NAFLD.•Elevated SIRI predicts greater risk of all-cause and cardiovascular mortality.•Ln-transforming SIRI yields linear relationships with mortality outcomes.